Ovarian Cancer Immunotherapy and Personalized Medicine.
biomarker
immunotherapy
ovarian cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Jun 2021
18 Jun 2021
Historique:
received:
26
04
2021
revised:
11
06
2021
accepted:
13
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.
Identifiants
pubmed: 34207103
pii: ijms22126532
doi: 10.3390/ijms22126532
pmc: PMC8234871
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Front Genet. 2015 Jun 17;6:215
pubmed: 26136771
Science. 2003 Apr 11;300(5617):286-90
pubmed: 12690187
Gynecol Oncol. 2013 Nov;131(2):493-8
pubmed: 23863359
Yonsei Med J. 2002 Dec;43(6):691-700
pubmed: 12497651
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
J Natl Cancer Inst. 2014 Apr 03;106(5):
pubmed: 24700803
J Gynecol Oncol. 2017 Nov;28(6):e77
pubmed: 29027395
Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95
pubmed: 25457975
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Clin Oncol. 2017 Apr 1;35(10):1112-1118
pubmed: 28029313
Clin Cancer Res. 2017 Dec 1;23(23):7263-7275
pubmed: 28947567
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
Jpn J Clin Oncol. 2019 Aug 1;49(8):789-792
pubmed: 31671191
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Cancer Res. 2018 Jul 1;24(13):3014-3025
pubmed: 29545464
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
J Gynecol Oncol. 2019 Sep;30(5):e105
pubmed: 31328467
Gynecol Oncol Rep. 2017 Jun 27;21:78-80
pubmed: 28736741
Pathology. 2016 Feb;48(2):177-87
pubmed: 27020390
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077
pubmed: 33409454
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Drugs. 2011 Jul 30;71(11):1397-412
pubmed: 21812505
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
Obstet Gynecol. 2012 Sep;120(3):612-8
pubmed: 22914471
J Transl Med. 2019 Nov 26;17(1):391
pubmed: 31771601
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Gynecol Oncol. 2021 Jun;161(3):676-680
pubmed: 33715892
Cancer Gene Ther. 2020 Dec;27(12):841-853
pubmed: 32341410
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Cell Rep. 2016 Jun 21;15(12):2719-32
pubmed: 27292635
Cold Spring Harb Perspect Biol. 2018 Mar 1;10(3):
pubmed: 28507022
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Hum Vaccin Immunother. 2015;11(12):2790-5
pubmed: 26308285
Clin Cancer Res. 2018 Sep 15;24(18):4416-4428
pubmed: 29848573
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91
pubmed: 22906947
Gynecol Oncol Rep. 2019 Aug 13;29:102-105
pubmed: 31467961
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Semin Cancer Biol. 2021 Jul;72:65-75
pubmed: 31698088
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
J Clin Oncol. 2011 Mar 1;29(7):925-33
pubmed: 21079136
J Clin Oncol. 2016 Jul 1;34(19):2271-8
pubmed: 27001568
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
Cancer Res. 2001 Jun 15;61(12):4766-72
pubmed: 11406550
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Clin Cancer Res. 2015 Aug 15;21(16):3631-9
pubmed: 25567908
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
Int J Cancer. 2008 Aug 1;123(3):609-15
pubmed: 18498132
Ann Oncol. 2017 May 1;28(5):996-1004
pubmed: 28453702
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Cell Physiol. 2019 Aug;234(10):16824-16837
pubmed: 30784085
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Oncotarget. 2020 Jun 02;11(22):2092-2105
pubmed: 32547707
Cancer Res. 2010 Oct 1;70(19):7465-75
pubmed: 20841473
Drugs. 2018 Feb;78(2):155-162
pubmed: 29350327
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626
pubmed: 29593010
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
Cancer Discov. 2017 Jul;7(7):675-693
pubmed: 28630051
Cancer Res. 2013 Feb 1;73(3):1128-41
pubmed: 23221383
J Clin Med. 2019 Mar 30;8(4):
pubmed: 30934991
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Cell. 2004 Aug 6;118(3):277-9
pubmed: 15294153
J Cancer. 2021 Jan 1;12(1):38-53
pubmed: 33391401
Int Immunopharmacol. 2020 Dec;89(Pt A):107126
pubmed: 33189611
Cancer Res. 1992 Jun 15;52(12):3396-401
pubmed: 1596899
Oncotarget. 2016 Dec 13;7(50):83476-83487
pubmed: 27825125
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Acta Histochem. 2015 May-Jun;117(4-5):367-78
pubmed: 25881478
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208030
Gynecol Oncol. 2019 Oct;155(1):51-57
pubmed: 31421916
J Clin Oncol. 2013 Apr 20;31(12):1554-61
pubmed: 23478059
Gynecol Oncol Rep. 2020 Sep 17;34:100648
pubmed: 33364285
J Immunol. 2005 Apr 15;174(8):4880-91
pubmed: 15814715
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Int J Gynecol Pathol. 2013 May;32(3):258-68
pubmed: 23518909
Cancer. 2009 Jul 1;115(13):2891-902
pubmed: 19472394
Immunol Rev. 1999 Aug;170:85-100
pubmed: 10566144
Histopathology. 2014 Nov;65(5):726-8
pubmed: 24750176
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Transl Oncol. 2020 Feb;13(2):410-422
pubmed: 31901781
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
Methods Mol Biol. 2016;1403:755-61
pubmed: 27076165
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Mol Ther. 2012 Mar;20(3):679-86
pubmed: 22186789
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Biomark Res. 2020 Jun 29;8:23
pubmed: 32612833
Gynecol Oncol. 2006 Apr;101(1):12-7
pubmed: 16263157
ESMO Open. 2017 Jul 3;2(2):e000213
pubmed: 28761757
Gynecol Oncol. 2016 Dec;143(3):504-510
pubmed: 27678295
Autophagy. 2015;11(10):1849-63
pubmed: 25893854
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Breast Cancer Res Treat. 2018 Sep;171(2):273-282
pubmed: 29858752
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s
pubmed: 30133561
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Front Immunol. 2020 Sep 10;11:2105
pubmed: 33013886
Nat Med. 2019 Mar;25(3):389-402
pubmed: 30842677
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091744
Cancer Immunol Immunother. 2019 Nov;68(11):1747-1757
pubmed: 31602489
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Cancer Immunol Immunother. 2019 Jan;68(1):121-130
pubmed: 30306202
Mol Cell. 2018 Sep 6;71(5):745-760.e5
pubmed: 30193098
Int J Gynecol Cancer. 2019 Jan 10;:
pubmed: 30630885
Oncology (Williston Park). 2013 Apr;27(4):288-94, 298
pubmed: 23781692
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Cancer Immunol Immunother. 2008 Jan;57(1):97-106
pubmed: 17602225
Cancer Res. 1991 Apr 1;51(7):1934-9
pubmed: 2004379
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
Front Immunol. 2020 Mar 04;11:364
pubmed: 32194568
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713
pubmed: 29788099
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Cancer Lett. 2019 May 28;450:88-97
pubmed: 30797818
Oncol Rep. 2007 Nov;18(5):1115-22
pubmed: 17914561
Int J Cancer. 1997 Apr 22;74(2):193-8
pubmed: 9133455
Gynecol Oncol Res Pract. 2017 Feb 22;4:4
pubmed: 28250960
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Front Oncol. 2019 Oct 15;9:1073
pubmed: 31681606
Ann Oncol. 2016 Aug;27(8):1449-55
pubmed: 27037296
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Nat Med. 2019 Oct;25(10):1488-1499
pubmed: 31591590
Evid Based Complement Alternat Med. 2013;2013:306705
pubmed: 23843871
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Mod Pathol. 2009 Mar;22(3):393-402
pubmed: 19060844
Immunotherapy. 2018 Jun;10(8):643-655
pubmed: 29562816